In the Original Investigation titled “SBRT vs HDR Brachytherapy for Intermediate-Risk Prostate Cancer,”1 published February 25, 2026, “adverse events” in panel titles and y-axis labels in Figure 2 was mislabeled as “toxic effects.” The article has been corrected.1
Reference
- 1.Udovicich C, Cheung P, Chu W, et al. SBRT vs HDR brachytherapy for intermediate-risk prostate cancer. JAMA Netw Open. 2026;9(2):e260146. doi: 10.1001/jamanetworkopen.2026.0146 [DOI] [PMC free article] [PubMed] [Google Scholar]
